Core Insights - Alector, Inc. has appointed Neil Berkley as Chief Financial Officer (CFO), effective December 10, 2025, while he continues to serve as Chief Business Officer (CBO) [1][2] Company Overview - Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, utilizing genetics, immunology, and neuroscience [3] - The company aims to address conditions such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia through its innovative product candidates [3] - Alector is developing the Alector Brain Carrier (ABC) platform to enhance therapeutic delivery across the blood-brain barrier, aiming for improved patient outcomes and cost reduction [3] Leadership Insights - Neil Berkley has over two decades of experience in corporate strategy, finance, business development, and operations within the biotech sector [2] - His leadership has been pivotal in advancing Alector's strategic priorities and strengthening partnerships since joining the company in 2024 [2] - Berkley's background includes founding two companies and serving on multiple biotech boards, showcasing his extensive industry experience [2]

PIRAEUS, Greece, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Navios Maritime Partners L.P. (“Navios Partners”) (NYSE: NMM), an international owner and operator of dry cargo and tanker vessels, today announced senior leadership changes. Angeliki Frangou, Chairwoman and Chief Executive Officer stated “Today marks the beginning of an exciting new chapter as we strengthen the executive management team and continue our mission of being a leading player in the maritime industry through rigorous risk management, prudent cap ...

NEWPORT BEACH, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today announced that its Special Meeting of Stockholders, originally scheduled to be held on December 10, 2025, was convened and immediately adjourned due to the absence of a quorum required to conduct business. The Special Meeting has been adjourned to February 4, 2026, at 11:00 a.m. Eastern time. A notice of the reconvened meeting date ...

Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-biotechnology company developing exosome-based therapies for central nervous system injuries, today announced meaningful progress in its long-term clinical-readiness strategy. The Company has begun the process of evaluating potential Israeli production partners ...

Kaldalón hf. (“Kaldalón”) and FÍ fasteignafélag slhf. (“FÍ fasteignafélag”) have signed Kaldalón’s purchase offer for all real estate assets owned by FÍ fasteignafélag. The property portfolio comprises 11 properties with a total floor area of approximately 25,200 square metres. All properties are located in the Greater Reykjavík area and include, among other things, a hotel, an embassy, a primary healthcare facility and office premises. Key assets within the portfolio include Hverfisgata 103, which houses a ...

Core Points - Park Dental Partners successfully completed its public listing on the Nasdaq Stock Market, with shares trading under the symbol "PARK" since December 3, 2025 [1] - The company aims to expand its stakeholder base and become a leader in the dental industry, emphasizing growth while maintaining a strong service culture [2] - Park Dental Partners provides comprehensive non-clinical business support services to over 200 dentists across 85 practice locations in Minnesota and Wisconsin, allowing practices to focus on patient care [3] Company Overview - Park Dental Partners is a dental resource organization that offers administrative support, clinical teams, and centralized services to affiliated dental practices [3] - The organization supports a full range of dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics [3]

Core Insights - The passing of J. Robert "Bob" Young marks a significant loss for Alpine Bank and the community, as he was a pivotal figure in its establishment and growth [2][4][5] - Young's legacy includes a commitment to community service, employee ownership, and a culture of integrity within the bank [3][5][6] Company Overview - Alpine Bank, founded in 1973, has grown to become a respected financial institution in Colorado with 39 locations and $6.8 billion in assets [3][6] - The bank employs 890 people and serves approximately 170,000 customers, offering a range of financial services [6] Leadership and Impact - Bob Young's leadership philosophy emphasized caring for others and community connection, which has shaped the bank's mission [2][5] - Young's initiatives included the introduction of an employee stock ownership plan (ESOP) in 1983, fostering employee investment in the bank's future [3] Community Engagement - Young was actively involved in community service and philanthropy, notably through the creation of the Alpine Bank First-Generation Scholarship, benefiting over 300 college students [4] - His contributions extended to leadership roles in the Colorado Bankers Association and the Colorado state banking board [4] Legacy and Future - The values instilled by Young continue to guide Alpine Bank, ensuring a commitment to community service and integrity [5] - The bank's five-star rating from BauerFinancial reflects its superior performance in the financial sector [6]

First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment ...

Core Viewpoint - Kaldalón hf. has successfully signed a purchase agreement for all real estate assets owned by FÍ fasteignafélag, marking a significant expansion of its property portfolio in the Greater Reykjavík area [1][3]. Property Portfolio Details - The acquired portfolio consists of 11 properties with a total floor area of approximately 25,200 square meters, including a hotel, an embassy, a primary healthcare facility, and office premises [2]. - Key assets include a 100-room hotel at Hverfisgata 103, office premises at Borgartún 25, an embassy at Laufásvegur 31, and a healthcare facility in Glæsibær [2]. Financial Aspects of the Transaction - The total purchase price is ISK 13,150 million, financed through the issuance of equity and bonds [4]. - The transaction involves the delivery of 228,112,591 new shares in Kaldalón and bonds amounting to ISK 7,232.5 million, with bonds issued at a yield of 3.93% [4]. - The issue price of the new shares is based on an average trading price of ISK 25.94 per share over the last 10 trading days prior to the offer acceptance [4]. Conditions for Completion - Completion of the transaction is contingent upon satisfactory technical inspections, approval from the Icelandic Competition Authority, and necessary amendments to bond terms [5][6]. Expected Financial Impact - The estimated increase in Kaldalón's annual net operating income (NOI) from the acquired properties is approximately ISK 870 million, with a potential increase to ISK 960 million upon full leasing of one development asset [7]. - Following the transaction, Kaldalón's total property portfolio will expand to approximately 170,000 square meters, with operating revenues expected to increase by approximately ISK 1,050 million annually [9]. Strategic Comments - The CEO of Kaldalón expressed satisfaction with the acquisition, highlighting the central location and strong tenant base of the properties, and the intention to streamline the portfolio to enhance revenue [8]. - The Chairman of the Board of FÍ Eignarhaldsfélag noted the successful development of FÍ fasteignafélag and the milestone achieved through this transaction [9][10].

HANGZHOU, Dec. 12, 2025 (GLOBE NEWSWIRE) -- JIUZI HOLDINGS, INC. (NASDAQ: JZXN) (the “Company”), today announced that it has entered into a definitive agreement with one investor for the purchase and sale of an aggregate of 1,600,000 of the Company’s Class A ordinary share, par value $0.078 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $2.5 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price f ...